Nasdaq Plrx News Today

Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) has been assigned an average rating of “Buy” from the nine brokerages that are covering the stock, MarketBeat reports. Nine research analysts have rated the stock with a buy rating. The average 1 year target price among brokers that have updated their coverage on the stock in […]

Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) has received an average rating of “Buy” from the nine brokerages that are covering the firm, MarketBeat.com reports. Nine equities research analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokerages that have covered the stock in the last year is […]

Pliant Therapeutics (NASDAQ:PLRX – Free Report) had its target price reduced by Royal Bank of Canada from $53.00 to $50.00 in a research report report published on Wednesday morning, Benzinga reports. Royal Bank of Canada currently has an outperform rating on the stock. PLRX has been the subject of a number of other research reports. […]

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They presently have a $48.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 190.56% from the stock’s previous close. Several […]

Rhenman & Partners Asset Management AB acquired a new stake in shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Free Report) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 330,635 shares of the company’s stock, valued at approximately $5,733,000. Rhenman & Partners Asset Management AB […]

Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) have earned a consensus recommendation of “Buy” from the eleven brokerages that are covering the stock, MarketBeat Ratings reports. Eleven analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have issued a report on the stock in […]

Bexotegrast (PLN-74809) at 320 mg was well tolerated over 12 weeks of treatment with no drug-related severe or serious adverse events; No safety concerns...

Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) was up 6.9% during mid-day trading on Monday . The stock traded as high as $18.32 and last traded at $18.32. Approximately 121,803 shares traded hands during mid-day trading, a decline of 71% from the average daily volume of 420,464 shares. The stock had previously closed at […]

Wells Fargo & Company assumed coverage on shares of Pliant Therapeutics (NASDAQ:PLRX – Free Report) in a research note released on Friday morning, Briefing.com reports. The brokerage issued an overweight rating and a $41.00 price objective on the stock. Several other equities analysts have also recently issued reports on PLRX. Leerink Partnrs reiterated an outperform […]

Pliant Therapeutics, Inc. (NASDAQ:PLRX – Free Report) – Cantor Fitzgerald boosted their FY2023 earnings per share (EPS) estimates for Pliant Therapeutics in a report released on Monday, November 13th. Cantor Fitzgerald analyst P. Stavropoulos now forecasts that the company will earn ($2.85) per share for the year, up from their previous forecast of ($3.01). Cantor […]